TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11068301

Group type: COMPARATOR
Intervention: Urinary cytology
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: DNA image cytometry (conventional analysis of DNA histograms)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: DNA image cytometry (Böcking interpretation)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: DNA image cytometry (grade 1 tumors)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Both methods (Urinary cytology and DNA image cytometry)
Number of subjects: 80
Study: 8807071

Group type: EXPERIMENTAL
Intervention: Rifabutin 600 mg/day
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 1361796

Group type: EXPERIMENTAL
Intervention: Clavulanate potentiated ticarcillin (TC)
Number of subjects: 14
Study: 6377466

Group type: EXPERIMENTAL
Intervention: 400 mg cimetidine daily
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: 25 mg trimipramine daily
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 29728861

Group type: EXPERIMENTAL
Intervention: Pharmacogenetic testing
Number of subjects: 0
Study: 30160183

Group type: EXPERIMENTAL
Intervention: Shortened contrast injection (8 seconds) in group A
Number of subjects: 106

Group type: COMPARATOR
Intervention: Standard contrast injection (10 seconds) in group B
Number of subjects: 106
Study: 26656425

Group type: EXPERIMENTAL
Intervention: 3-D virtual reality kayak program
Number of subjects: 72

Group type: COMPARATOR
Intervention: Conventional exercise program
Number of subjects: 72
Study: 25198417

Group type: EXPERIMENTAL
Intervention: RealConsent
Number of subjects: 743
Study: 22541837

Group type: EXPERIMENTAL
Intervention: Febuxostat 80 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 19394469

Group type: EXPERIMENTAL
Intervention: Ice cream (3% butterfat)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ice cream (9% coconut oil)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Reduced-fat milk (1.7% milk fat)
Number of subjects: 16
Study: 17991635

Group type: EXPERIMENTAL
Intervention: 8.3% trans FA diet
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 14.6% polyunsaturated FA diet
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 13.2% saturated FA diet
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: HDL(3)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: HDL(2)
Number of subjects: 30
Study: 16884836

Group type: EXPERIMENTAL
Intervention: AgB/RC‐210‐04 (n=136)
Number of subjects: 285

Group type: COMPARATOR
Intervention: AgB (n=149)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: AgB/RC‐210‐04
Number of subjects: 285
Study: 12926838

Group type: EXPERIMENTAL
Intervention: 0.6 million international units (MIU) of oral interferon beta-1a
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: 0.06 million international units (MIU) of oral interferon beta-1a
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: 6 million international units (MIU) of oral interferon beta-1a
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: All groups (including placebo)
Number of subjects: 173
Study: 11005498

Group type: EXPERIMENTAL
Intervention: Rectal mobilization
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Division of lateral ligaments
Number of subjects: 18

Group type: COMPARATOR
Intervention: Preservation of lateral ligaments
Number of subjects: 18
Study: 8851739

Group type: EXPERIMENTAL
Intervention: Orientation of the frame
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interference task
Number of subjects: 0
Study: 1457264

Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (4 x 100 micrograms)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral salbutamol (4 mg)
Number of subjects: 0
Study: 6363157

Group type: EXPERIMENTAL
Intervention: Acidrine (2 tablets t.i.d. for 8 weeks)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (2 tablets t.i.d. for 8 weeks)
Number of subjects: 39
Study: 29313802

Group type: EXPERIMENTAL
Intervention: Cognitive training combined with tDCS
Number of subjects: 360

Group type: COMPARATOR
Intervention: Education training-control combined with sham tDCS
Number of subjects: 360
Study: 26324322

Group type: EXPERIMENTAL
Intervention: Stabilization treatment
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Movement System Impairment (MSI) treatment
Number of subjects: 68
Study: 25148644

Group type: EXPERIMENTAL
Intervention: Deproteinized bovine bone graft (Bio‐Oss) and absorbable collagen membrane (Bio‐Gide)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 22367794

Group type: EXPERIMENTAL
Intervention: Immunonutrition (1000 ml/day for 5 days before surgery)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Control (regular diet)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Immunonutrition
Number of subjects: 244

Group type: COMPARATOR
Intervention: Control
Number of subjects: 244
Study: 20636739

Group type: EXPERIMENTAL
Intervention: Mandibular advancement splint
Number of subjects: 52

Group type: COMPARATOR
Intervention: Bite raising appliance
Number of subjects: 52
Study: 18558642

Group type: EXPERIMENTAL
Intervention: Olanzapine plus day hospital treatment
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo plus day hospital treatment
Number of subjects: 34
Study: 16051573

Group type: EXPERIMENTAL
Intervention: Light clothing
Number of subjects: 10

Group type: COMPARATOR
Intervention: Dark clothing
Number of subjects: 10
Study: 12480497

Group type: EXPERIMENTAL
Intervention: recombinant human IL-2 at doses of 10,000 IU/kg bw
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: recombinant human IL-2 at doses of 1000 IU/kg bw
Number of subjects: 18

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study: 10361648

Group type: EXPERIMENTAL
Intervention: Videotape intervention (two different approaches)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Videotape portraying recovery as ups and downs
Number of subjects: 216

Group type: COMPARATOR
Intervention: Standard discharge preparation (control)
Number of subjects: 216
Study: 8520751

Group type: EXPERIMENTAL
Intervention: Salmeterol (50 micrograms twice daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 1902866

Group type: EXPERIMENTAL
Intervention: 250 mg/kg intravenous immunoglobulin
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: 500 mg/kg intravenous immunoglobulin
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (no immunoglobulin)
Number of subjects: 102
Study: 7295451

Group type: EXPERIMENTAL
Intervention: Enflurane anesthesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Halothane anesthesia
Number of subjects: 0
Study: 31087630

Group type: EXPERIMENTAL
Intervention: Dalbavancin
Number of subjects: 0
Study: 30238636

Group type: EXPERIMENTAL
Intervention: Garlic powder (2g, 11mg allicin)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 28283493

Group type: EXPERIMENTAL
Intervention: Data-driven Quality Improvement in Primary Care (DQIP) intervention
Number of subjects: 10
Study: 25440816

Group type: EXPERIMENTAL
Intervention: Flexible Ureteroscopy (F‐URS)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Shock Wave Lithotripsy (SWL)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 150
Study: 22957483

Group type: EXPERIMENTAL
Intervention: tongue protector and 0.5 ml AV at 70% three times a day
Number of subjects: 75

Group type: COMPARATOR
Intervention: tongue protector and 0.5 ml placebo three times a day
Number of subjects: 75

Group type: COMPARATOR
Intervention: tongue protector three times a day
Number of subjects: 75
Study: 21226818

Group type: EXPERIMENTAL
Intervention: Dapagliflozin (2.5-50 mg in SAD study; 2.5-20 mg QD for 14 days in MAD study)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 3-O-glucuronide (inactive metabolite)
Number of subjects: 68
Study: 18784840

Group type: EXPERIMENTAL
Intervention: Long-term ITN (Serena brand) social marketing plus free ITN (Serena brand) distribution to all pregnant women attending governmental antenatal care services (group A)
Number of subjects: 1050

Group type: COMPARATOR
Intervention: ITN social marketing only (group B)
Number of subjects: 1050
Study: 16609353

Group type: EXPERIMENTAL
Intervention: Rest gated 201Tl myocardial perfusion SPECT
Number of subjects: 81

Group type: COMPARATOR
Intervention: 2-D echocardiography (2-D ECHO)
Number of subjects: 81
Study: 12505559

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Free choice (FC) control condition
Number of subjects: 0
Study: 11027924

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 95

Group type: COMPARATOR
Intervention: Nortriptyline
Number of subjects: 95
Study: 8647351

Group type: EXPERIMENTAL
Intervention: Propranolol (beta-adrenoceptor antagonist)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Alprazolam (benzodiazepine)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 1417632

Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 48

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 48
Study: 3883741

Group type: EXPERIMENTAL
Intervention: Bepridil plus propranolol
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo plus propranolol
Number of subjects: 56
Study: 30791884

Group type: EXPERIMENTAL
Intervention: Telephone invitation
Number of subjects: 4614

Group type: EXPERIMENTAL
Intervention: Personalised letter
Number of subjects: 4614

Group type: COMPARATOR
Intervention: Standard letter (control)
Number of subjects: 4614
Study: 29426388

Group type: EXPERIMENTAL
Intervention: Home-based occupational therapy intervention
Number of subjects: 30
Study: 26002786

Group type: EXPERIMENTAL
Intervention: Pressure Dressing (PD)
Number of subjects: 1650

Group type: EXPERIMENTAL
Intervention: Pneumatic Compression Device (PCD)
Number of subjects: 1650

Group type: EXPERIMENTAL
Intervention: Rotary Compression Pad Device (RCD)
Number of subjects: 1650
Study: 23579002

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (SB) supplementation (0.3 g/kg body mass)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (PLA; maltodextrin)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (SB) supplementation
Number of subjects: 20
Study: 23573950

Group type: EXPERIMENTAL
Intervention: Givinostat 50 mg/d
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Givinostat 100 mg/d
Number of subjects: 44

Group type: COMPARATOR
Intervention: Hydroxycarbamide (HC)
Number of subjects: 44
Study: 19912183

Group type: EXPERIMENTAL
Intervention: Propiverine 20 mg once daily
Number of subjects: 221

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study: 18825471

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training for 10 months
Number of subjects: 57
Study: 16626265

Group type: EXPERIMENTAL
Intervention: Individual video review
Number of subjects: 128

Group type: COMPARATOR
Intervention: Group video review
Number of subjects: 128
Study: 12745638

Group type: EXPERIMENTAL
Intervention: Prostate cancer patients with a fixed view of masculinity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prostate cancer patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-patients
Number of subjects: 0
Study: 11224624

Group type: COMPARATOR
Intervention: Chronic pancreatitis patients
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Chronic pancreatitis patients post-resection
Number of subjects: 28
Study: 10205316

Group type: EXPERIMENTAL
Intervention: Folate supplementation (5 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 20
Study: 7933523

Group type: EXPERIMENTAL
Intervention: Biapenem (L-627) administered intravenously at daily doses of 17-37.5 mg/kg for 4-7 consecutive days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Biapenem (L-627) at a dose of 6 mg/kg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Biapenem (L-627) at a dose of 12 mg/kg
Number of subjects: 12
Study: 3063133

Group type: EXPERIMENTAL
Intervention: Propofol (2 mg/kg bolus, then 0.2 mg/kg/min infusion for 10 min)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Diazepam (0.3 mg/kg bolus)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Thiopental (5 mg/kg bolus)
Number of subjects: 30
Study: 31125155

Group type: EXPERIMENTAL
Intervention: NTP treatment
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Sofreliner Primer
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: NTP + Sofreliner Primer
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Sofreliner Primer + NTP
Number of subjects: 164
Study: 28856857

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine-remifentanil
Number of subjects: 80

Group type: COMPARATOR
Intervention: Midazolam-remifentanil
Number of subjects: 80
Study: 24556057

Group type: EXPERIMENTAL
Intervention: Nursing Delirium Screening Scale (Nu‐DESC)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Edmonton Assessment Scale (ESAS)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Memorial Delirium Assessment Scale (MDAS)
Number of subjects: 78
Study: 23788632

Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation (n = 40)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (n = 40)
Number of subjects: 80
Study: 21764087

Group type: EXPERIMENTAL
Intervention: Informed choice invitation
Number of subjects: 1272

Group type: COMPARATOR
Intervention: Standard invitation
Number of subjects: 1272
Study: 19436100

Group type: EXPERIMENTAL
Intervention: Robust optimization method for IMRT plans
Number of subjects: 1

Group type: COMPARATOR
Intervention: Non-robust optimized plan
Number of subjects: 1
Study: 16936704

Group type: EXPERIMENTAL
Intervention: Delta‐9‐tetrahydrocannabinol (Delta‐9‐THC)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 15238771

Group type: EXPERIMENTAL
Intervention: FPV/r QD
Number of subjects: 649

Group type: COMPARATOR
Intervention: NFV BID
Number of subjects: 649
Study: 11691690

Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg/day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 12
Study: 9408700

Group type: EXPERIMENTAL
Intervention: Mesigyna (50 mg norethisterone enanthate and 5 mg estradiol valerate)
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Cyclofem (25 mg medroxyprogesterone acetate and 5 mg estradiol cypionate)
Number of subjects: 357
Study: 8427367

Group type: EXPERIMENTAL
Intervention: Water running
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Cycling
Number of subjects: 32

Group type: COMPARATOR
Intervention: Running training
Number of subjects: 32
Study: 31471088

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser treatment
Number of subjects: 132

Group type: COMPARATOR
Intervention: Untreated vitreous floaters
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Participants seeking vitrectomy (previously treated with Nd:YAG)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control participants without vitreous floaters
Number of subjects: 132
Study: 30073253

Group type: EXPERIMENTAL
Intervention: Topical dornase alfa (5 drops each ear twice a day for 7 days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ofloxacin (5 drops each ear twice a day for 7 days)
Number of subjects: 40
Study: 27007392

Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (4 g)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: CoQ (200 mg)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Both supplements (n-3 fatty acids and CoQ)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control (4 g olive oil)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Post-intervention plasma F₂-isoprostanes
Number of subjects: 85
Study: 24802626

Group type: EXPERIMENTAL
Intervention: Magnet group (ICD therapy suspended with a magnet)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Off group (ICD therapy programmed off)
Number of subjects: 80
Study: 22374377

Group type: EXPERIMENTAL
Intervention: S-Ketamine (0.5 mg/kg i.m. bolus followed by 2 μg/kg/min i.v. continuous infusion for 12 h)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 56
Study: 20919483

Group type: EXPERIMENTAL
Intervention: Tele-care self-management support model (ATAS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (Control Group, CG)
Number of subjects: 0
Study: 18565884

Group type: COMPARATOR
Intervention: Radiation therapy (RT) alone
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Radiation therapy (RT) with 6 months of combined androgen suppression therapy (AST)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Radiation therapy (RT) with less than 6 months of combined androgen suppression therapy (AST)
Number of subjects: 206
Study: 16043985

Group type: COMPARATOR
Intervention: RDP58 100 mg
Number of subjects: 127

Group type: COMPARATOR
Intervention: RDP58 200 mg
Number of subjects: 127

Group type: COMPARATOR
Intervention: RDP58 300 mg
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 127
Study: 12502122

Group type: EXPERIMENTAL
Intervention: 0.5% fluorouracil topical cream applied once daily for 1, 2, or 4 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.5% fluorouracil topical cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 0
Study: 10049964

Group type: EXPERIMENTAL
Intervention: Supine sleeping position
Number of subjects: 16

Group type: COMPARATOR
Intervention: Prone sleeping position
Number of subjects: 16
Study: 7718459

Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin (300 mg) daily for 4 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (one tablet) daily for 4 months
Number of subjects: 20
Study: 2381302

Group type: EXPERIMENTAL
Intervention: Dicalcium phosphate (129 mmol) and glucose (500 ml/10% sol)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 7287918

Group type: EXPERIMENTAL
Intervention: Experimental group (left-ear responses reinforced)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 30911274

Group type: EXPERIMENTAL
Intervention: First-line chemotherapy
Number of subjects: 82

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 82
Study: 30152390

Group type: EXPERIMENTAL
Intervention: Oral steroids (prednisolone)
Number of subjects: 389

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 389
Study: 27451030

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 24387127

Group type: EXPERIMENTAL
Intervention: Skeletonized grafting
Number of subjects: 50

Group type: COMPARATOR
Intervention: Pedicled grafting
Number of subjects: 50
Study: 22527435

Group type: EXPERIMENTAL
Intervention: Clindamycin phosphate 1.2%/BPO 2.5% gel
Number of subjects: 797

Group type: COMPARATOR
Intervention: Control group (Fitzpatrick skin types IV-VI)
Number of subjects: 797
Study: 19438928

Group type: EXPERIMENTAL
Intervention: High-frequency rTMS (10 Hz) conditioning
Number of subjects: 18

Group type: COMPARATOR
Intervention: 1 Hz rTMS alone
Number of subjects: 18

Group type: COMPARATOR
Intervention: 1 Hz rTMS in healthy controls
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham conditioning
Number of subjects: 18
Study: 18098001

Group type: EXPERIMENTAL
Intervention: Methamphetamine treatment approaches
Number of subjects: 1016
Study: 15606443

Group type: EXPERIMENTAL
Intervention: Trimethoprim 200 mg given twice daily for 5 days
Number of subjects: 8
Study: 12089223

Group type: EXPERIMENTAL
Intervention: 1.0 mg/m2 oral topotecan with 1,000 mg GF120918
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 1.0 mg/m2 intravenous topotecan with 1,000 mg GF120918
Number of subjects: 16

Group type: COMPARATOR
Intervention: 1.0 mg/m2 oral topotecan without GF120918
Number of subjects: 16

Group type: COMPARATOR
Intervention: 1.0 mg/m2 intravenous topotecan without GF120918
Number of subjects: 16
Study: 9453518

Group type: EXPERIMENTAL
Intervention: Tissue-type plasminogen activator with heparin estimated by aPTT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moderate decrease in fibrinogen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Large decrease in fibrinogen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher fibrinogen and plasminogen values at baseline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Frequent monitoring of aPTT during the first 24 to 48 hours
Number of subjects: 0
Study: 7822520

Group type: EXPERIMENTAL
Intervention: terbinafine, 250 mg/day
Number of subjects: 180

Group type: COMPARATOR
Intervention: griseofulvin, 500 mg/day
Number of subjects: 180
Study: 2225640

Group type: EXPERIMENTAL
Intervention: Patellar resurfacing in the right knee
Number of subjects: 25

Group type: COMPARATOR
Intervention: Non-resurfacing in the left knee
Number of subjects: 25
Study: 682218

Group type: EXPERIMENTAL
Intervention: Albumin (25 gm during operation and 150 gm/day for 3 to 5 days thereafter)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Non-albumin resuscitation
Number of subjects: 52
Study: 30707970

Group type: EXPERIMENTAL
Intervention: Soy isoflavones
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Genistein treatment
Number of subjects: 265

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 265
Study: 30057104

Group type: EXPERIMENTAL
Intervention: High-dose PPI (40 mg twice-daily)
Number of subjects: 2557

Group type: COMPARATOR
Intervention: Low-dose PPI (20 mg once-daily)
Number of subjects: 2557

Group type: EXPERIMENTAL
Intervention: Aspirin (300 mg per day in the UK, 325 mg per day in Canada)
Number of subjects: 2557

Group type: COMPARATOR
Intervention: No aspirin
Number of subjects: 2557

Group type: EXPERIMENTAL
Intervention: Combination of high-dose PPI and aspirin
Number of subjects: 2557

Group type: COMPARATOR
Intervention: Low-dose PPI without aspirin
Number of subjects: 2557
Study: 25759177

Group type: EXPERIMENTAL
Intervention: Home-based oral care training programme
Number of subjects: 94

Group type: COMPARATOR
Intervention: Routine oral care education
Number of subjects: 94